Cargando…

Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience

PURPOSE: To evaluate the outcomes of 5-year ranibizumab treatment in neovascular age-related macular degeneration (nAMD) in a single center and real life clinical setting. METHODS: The records of nAMD patients who were treated with ranibizumab between January 2010 and June 2011 were retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozkaya, Abdullah, Alkin, Zeynep, Togac, Mesut, Ahmet, Sibel, Perente, Irfan, Taskapili, Muhittin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Ophthalmological Society 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636718/ https://www.ncbi.nlm.nih.gov/pubmed/28913999 http://dx.doi.org/10.3341/kjo.2016.0125

Ejemplares similares

Real-Life Data of Patients with Exudative Age-Related Macular Degeneration
por: Togac, Mesut, et al.
Publicado: (2021)

Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Comparison of intravitreal ranibizumab between phakic and pseudophakic neovascular age-related macular degeneration patients: Two-year results
por: Ozkaya, Abdullah, et al.
Publicado: (2015)

Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration?
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Thickness of the retinal photoreceptor outer segment layer in healthy volunteers and in patients with diabetes mellitus without retinopathy, diabetic retinopathy, or diabetic macular edema
por: Ozkaya, Abdullah, et al.
Publicado: (2017)

Intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to morning glory syndrome in a child
por: Özkaya, Abdullah, et al.
Publicado: (2016)

The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab
por: Alkin, Zeynep, et al.
Publicado: (2013)

Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022)

The comparison of multimodal imaging findings of central serous chorioretinopathy patients in regard to the early anatomically treatment response to half-fluence photodynamic therapy: a retrospective case–control study
por: Ozkaya, Abdullah, et al.
Publicado: (2017)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
por: Chang, Yi-Sheng, et al.
Publicado: (2018)

Assessment of the macula and choroid in pediatric keratoconus patients
por: Yilmaz, Ihsan, et al.
Publicado: (2018)

Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia
por: Baz, Ökkeş, et al.
Publicado: (2017)

Focal Laser Photocoagulation in Non-Center Involved Diabetic Macular Edema
por: Perente, Irfan, et al.
Publicado: (2014)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Evaluation of Contrast Sensitivity after Single Intravitreal Triamcinolone Injection for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Aras Ogreden, Tulin, et al.
Publicado: (2013)

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)

Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)

Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1
por: Özkaya, Abdullah, et al.
Publicado: (2018)

Clinical Use of Dexamethasone Implants in Resistant Macular Edema Secondary to Branch Retinal Vascular Occlusion Compared with Intravitreal Anti-Vascular Endothelial Growth Factor
por: Eris, Erdem, et al.
Publicado: (2019)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin, Philip, et al.
Publicado: (2016)

Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
por: Gohil, Rishma, et al.
Publicado: (2016)

Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
por: Kaiser, Peter K.
Publicado: (2007)

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
por: Rotsos, Tryfon, et al.
Publicado: (2010)

Machine Learning to Predict Response to Ranibizumab in Neovascular Age-Related Macular Degeneration
por: Maunz, Andreas, et al.
Publicado: (2023)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study
por: Holz, Frank G., et al.
Publicado: (2020)

Visual outcome of ranibizumab therapy for neovascular age related macular degeneration in the black population: a report of five cases
por: Vemala, Roopa, et al.
Publicado: (2010)

Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
por: Chan, Clement K., et al.
Publicado: (2023)

Ocular Pulse Amplitude and Retinal Vessel Caliber Changes after Intravitreal Dexamethasone Implant
por: Yilmaz, Ihsan, et al.
Publicado: (2016)

Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
por: Scalzo, G C, et al.
Publicado: (2010)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
por: Haensli, Christof, et al.
Publicado: (2021)

Influence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degeneration
por: Nita, Małgorzata, et al.
Publicado: (2014)

Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration
por: Gohil, Rishma, et al.
Publicado: (2015)

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial
por: Russo, Andrea, et al.
Publicado: (2018)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova, Nadezhda P, et al.
Publicado: (2016)

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany
por: Wachtlin, Joachim, et al.
Publicado: (2020)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bqjpr41d59drp0a459r6j5v2lf